Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.

Pharmacogenetics and genomics - 1 Nov 2014

Zhang Ling Ling, Yang Sen, Wei Wei, Zhang Xue Jun

Abstract excerpt

Disease-modifying antirheumatic drugs (DMARDs) and biological agents are critical in preventing the severe complications of rheumatoid arthritis (RA). However, the outcome of treatment with these drugs in RA patients is quite variable and unpredictable. Drug-metabolizing enzymes (dihydrofolate reductase, cytochrome P450 enzymes, N-acetyltransferases, etc.), drug transporters (ATP-binding cassette transporters),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to B-Cell Activating Factor

Share to Cytochromes

Share to Interleukin-6

Share to Methyltransferases

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 25144752
DOI: 10.1097/FPC.0000000000000085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.PMID 25144752Read ↗

Pharmacogenetics of disease-modifying anti-rheumatic drugs.Semantic proximity Read ↗

Pharmacogenetics of therapies in rheumatoid arthritis: An update.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis.Semantic proximity Read ↗

Factors Underlying Failure of Methotrexate Treatment in Rheumatoid Arthritis: Implications in Personalized CareSemantic proximity Read ↗

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Semantic proximity Read ↗

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.Semantic proximity Read ↗

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysisSemantic proximity Read ↗

Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics in rheumatology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.